On 20 March 2018 Intrum completed the sale of the remedy units (RemCo) to Lowell having received the necessary regulatory approvals. This is in line with what was communicated on 2 November 2017.
RemCo was sold at an enterprise value of approximately €730m.
“We are happy to complete the sale of RemCo to Lowell and are pleased that we have found a strong new owner for our former colleagues. The proceeds further strengthen our financial position and we look forward to deploying them as we invest for future growth”, says Mikael Ericson, CEO & President of Intrum.
For further information, please contact:
Mikael Ericson, President & CEO, tel: +46 8 546 102 02
Louise Bergström, Head of Investor Relations tel: +46 8 546 103 42
This information was submitted for publication, through the agency of the contact person set out above, at 17.30 CET on 18.03.20.